Gensciences Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

Nantong Jiangsu China

Primary Industry

Biotechnology

About

Founded in 2019 and based in Nantong, China, Gensciences is a biopharmaceutical company that focuses on the research and development of innovative drugs for hemophilia. It currently has 61 patents in the filing and granted, with an R&D team of 150 members. Yali Wang, the chairman of the company, graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, with 30 years of experience in drug research and development. It has R&D centers in Beijing and Zhengzhou, as well as production bases and marketing branches in Shanghai. In November 2023, it received FDA IND approval for the recombinant factor VIII product. In June 2024, Gensciences closed a strategic investment. Gensciences mainly engages in the research and development of recombinant protein-based innovative drugs and related products. The company set up a bio-innovative drug development system and multiple technology platforms, which can meet the product development of cell culture, microbial fermentation, and other expression systems, covering fusion proteins, protein modification, and other technologies. It currently has 4 innovative drugs that entered clinical development, which are FRSW107, FRSW117, SS109, and SS327. Products can be used in hemophilia, metabolic diseases, and antitumor areas. The company generates revenue by providing recombinant protein-based innovative drugs and related products. In the future, the company will continue to develop bio-innovative drugs in the fields of coagulation and metabolic diseases.

Current Investors

IDG Capital, Cowin Capital, New Alliance Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Healthcare IT, Healthcare Specialists, Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development

Website

www.gensciences.com

Verticals

HealthTech, Manufacturing

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.